LOS ANGELES, July 10 /PRNewswire-FirstCall/ -- Signalife, Inc. has announced that The United States Patent and Trademark Office has awarded the Company a new and important patent, which the Company has now added to its significant intellectual property portfolio.
The patent, which covers 56 claims, was awarded on all such claims by the Patent Office. Patent attorney and Signalife’s Board member Ellsworth Roston supervised and prosecuted the patent application along with Chief Technology Officer Budimir S. Drakulic - the Company’s inventor. The new patent is owned by Signalife, Inc.
In conjunction with the Patent Office’s granting of the patent - entitled “Electrode For, and Method Of, Indicating Signal Characteristics At Particular Positions In A Patient’s Body” - the Company will now evaluate whether or not it will file a continuation or continuation-in-part application for the purpose of pursuing additional claim coverage in the technology that may have occurred since the time of the original application.
Budimir Drakulic called the patent-issuance-development a “major milestone in the continued proliferation and protection of the Company’s core technologies and products.” Dr. Drakulic said he was gratified at the “many years of enormous expertise and energy that Mr. Roston has expended in the prosecution of all patents as well in the development of the Company’s sophisticated intellectual property position.”
The medical device maker currently has an application for its “credit card” size, over the counter (non-prescription), device pending before the Food and Drug Administration as well as several additional patents pending before the United States Patent and Trademark Office covering a wide array of cardiac technologies and products. Dr. Drakulic stated that he is “confident the Company will continue to be successful in obtaining approval of its technologies and products in these endeavors.”
About Signalife
Signalife, Inc. is a life sciences company focused on the monitoring and detection of disease through continuous biomedical signal monitoring. Signalife uses its patented signal technology to design and develop medical devices that simplify and reduce the costs of diagnostic testing and patient monitoring in an ambulatory setting.
Signalife is publicly traded on the American Stock Exchange under the symbol SGN. The website for the company is http://www.Signalife.com. Clear Data. Trusted Results.
Caution Regarding Forward-Looking Statements
Statements in this release that are not strictly historical are “forward- looking” statements. Forward-looking statements involve known and unknown risks, which may cause Signalife’s actual results in the future to differ materially from expected results. Factors which could cause or contribute to such differences include, but are not limited to, failure to complete the development and introduction of heart monitoring and other biomedical devices incorporating Signalife’s technology, failure to obtain federal or state regulatory approvals governing heart monitoring and other biomedical devices incorporating Signalife’s technology, inability to obtain physician, patient or insurance acceptance of for heart monitoring and other biomedical incorporating Signalife’s technology, and the unavailability of financing to complete management’s plans and objectives, including the development of heart monitoring and other biomedical incorporating Signalife’s technology. These risks are qualified in their entirety by cautionary language and risk factors set forth and to be further described in Signalife’s filings with the Securities and Exchange Commission.
Signalife, Inc.
CONTACT: Kevin Kading for Signalife, Inc., +1-212-918-4606,kdng@prodigy.net
Web site: http://www.signalife.com//
